Sample features

SA Suzan van Amerongen
SP Surya V. Pulukuri
FT Fatima Tuz-Zahra
YT Yorghos Tripodis
JC Jonathan D. Cherry
CB Charles Bernick
YG Yonas E. Geda
JW Jennifer V. Wethe
DK Douglas I. Katz
MA Michael L. Alosco
CA Charles H. Adler
LB Laura J. Balcer
NA Nicholas J. Ashton
KB Kaj Blennow
HZ Henrik Zetterberg
DD Daniel H. Daneshvar
EC Elizabeth A. Colasurdo
JI Jeffrey J. Iliff
GL Gail Li
EP Elaine R. Peskind
MS Martha E. Shenton
ER Eric M. Reiman
JC Jeffrey L. Cummings
RS Robert A. Stern
request Request a Protocol
ask Ask a question
Favorite

Demographic characteristics, medical history, medication use, and alcohol/substance use were collected through interviews and questionnaires. Race and ethnicity were self-identified, participants self-identified as ‘White’, ‘Black or African American’, ‘Native Hawaiian or other Pacific Islanders’ and ‘Multiple Races’. For analysis purposes, we combined the latter three into one variable, resulting in two race categories. Body mass index (BMI) was calculated using current height and weight. The Alcohol Use Disorders Identification Test (AUDIT), a 10-item screening tool, provided a total score for alcohol consumption (range 0–40) [19]. Apolipoprotein E (APOE) genotyping was performed to identify carriers and non-carriers of the APOE-ε4 allele. The revised Framingham Stroke Risk Profile (rFSRP) score was calculated to determine vascular risk factors. [20] Other relevant medical history included a self-reported questionnaire on sleep apnea diagnosis.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A